Unconfigured Ad

Collapse
X
 
  • Time
  • Show
Clear All
new posts
  • Laurence Game
    Junior Member
    • May 2008
    • 5

    #1

    NexteraXT sequencing primers sequences

    hi, I want to run NexteraXT libraries on the HiSeq and would like to order my own stocks of sequencing primers HP10, HP12 and HP11 rather than the Illumina dual index sequencing kit.

    Has anyone worked out the sequences for these sequencing primers so that I can double check them with what I've worked out from the official Illumina Customer sequence letter from Sept 2012.

    Thanks
  • pmiguel
    Senior Member
    • Aug 2008
    • 2328

    #2
    I don't have an answer, but it is worth noting that it looks like Illumina uses different oligos, depending on the platform. I draw this conclusion because the specifications for custom oligos for the MiSeq emphasizes this point.

    Also, let me toss in my obligatory denunciation of Illumina for obscuring this information. I think it would be helpful if granting agencies forbade using black-boxed methodologies of this sort. I double Illumina gets much (if anything) out of hiding this information from their customers. So any sort of regulatory nudge would be likely to move them from this absurd position.

    --
    Phillip

    Comment

    • SeqR&D
      Member
      • Sep 2010
      • 26

      #3
      why would a company give up a secret that is making them money, so that you can buy it from someone else? they do give you a way to use your own sequencing primers...what more could you want? Can you just order the sequencing primers from them individually?

      Comment

      • james hadfield
        Moderator
        Cambridge, UK
        Community Forum
        • Feb 2008
        • 224

        #4
        Yes you can buy the oligos from Illumina, but at a ludicrous cost compared to buying an oligo from most providers. Illumina's big loss would be for Agilent and Nimblegen to use the sequence information to produce blocking oligos for ther capture kits. This would allow them to offer Nextera based capture, an easy way to 50ng input capture preps. Something they are sorely lacking.

        Of course any academic wanting to do the same could mess around or just buy TruSeq capture kits. I am sure illumina would prefer to keep these sequences locked down, but this is futile given the ease of sequencing a library to find out the base composition.

        I agree with pmiguel's sentiments. Illumina have little to fear if their IP is good as commercial use would be in breach and they could litigate. Making sequence information hard to get hold of is a pain.

        Comment

        • pmiguel
          Senior Member
          • Aug 2008
          • 2328

          #5
          Originally posted by james hadfield View Post
          I agree with pmiguel's sentiments. Illumina have little to fear if their IP is good as commercial use would be in breach and they could litigate. Making sequence information hard to get hold of is a pain.
          My guess is they are doing this as part of some agreement with someone they are licensing a technology from. At least that is an issue I have seen cause otherwise rational corporations act irrationally in the past.

          That is why I think the answer is for the granting agencies to ban use of closed source technology of this type. Would make sense as it is questionable whether you are really doing science at all when relying on reagents of undisclosed composition from a 3rd party.

          --
          Phillip

          Comment

          Latest Articles

          Collapse

          • SEQadmin2
            Multiomic Liquid Biopsy: What DNA/RNA Panels Reveal That DNA Alone Can’t
            by SEQadmin2



            Tumors contain complex mixtures of cell populations that evolve in response to treatment and host-specific factors. Tissue biopsies provide only static snapshots of a tumor’s state. But what if we could follow that evolution over time using a minimally invasive technique?

            Liquid biopsies can detect tumor-derived material circulating in the bloodstream, providing a way to study treatment response, detect emerging resistance, and discover new biomarkers. Circulating
            ...
            10-14-2026, 09:55 AM
          • SEQadmin2
            New Genomics Technologies Take Aim at Long-Standing Limits
            by SEQadmin2


            Researchers using sequencing and genomics tools often have to make trade-offs. They can choose between speed or scale, short reads or long-range information, or targeted panels or a view of the whole transcriptome. New technologies that have been released this year are built to address those tough choices.

            We asked six companies the same four questions to learn about their latest products. The new technologies bring a lot to the table, including rethinking sequencing
            ...
            09-28-2026, 10:25 AM

          ad_right_rmr

          Collapse

          News

          Collapse

          Topics Statistics Last Post
          Started by SEQadmin2, 10-22-2026, 11:13 AM
          0 responses
          23 views
          0 reactions
          Last Post SEQadmin2  
          Started by SEQadmin2, 10-22-2026, 10:48 AM
          0 responses
          20 views
          0 reactions
          Last Post SEQadmin2  
          Started by SEQadmin2, 10-15-2026, 10:52 AM
          0 responses
          36 views
          0 reactions
          Last Post SEQadmin2  
          Started by SEQadmin2, 10-14-2026, 05:39 AM
          0 responses
          42 views
          0 reactions
          Last Post SEQadmin2  
          Working...